September 25 2017

Rick Smith Leading the Creation of Innovative Solutions that Make Safety a Priority

In 2015, Rick Smith, Securus CEO, announced the signing of a Stock Purchase Agreement that finalized the acquisition of JPay Inc. by the company. The transactions made Securus one of the fastest growing providers of correctional related services that include payments, tablets, and emails. Also, it helped Securus increase its products to include a variety of software-based services and products and more information click here.

Securus Technology serves over 2600 corrections, public safety, and law enforcement agencies reaching over 1 million inmates. With its headquarter in Dallas, the company provides biometric analysis, communication, incident management, inmate self-service, emergency response, investigations and monitoring solutions. For a long time, Securus had admired the impressive and innovative business model of JPay.

JPay, a leading technology company, has revolutionized correctional facilities through the introduction of educational apps, video visitations, electronic payments and entertainment apps. The company products reach over 33. The mission of Jpay is to leverage technology to enhance efficiency in correctional facilities, reduce recidivism and avert crime. Other than payment services, JPay offers a digital platform that incorporates the use of inmate cloud, kiosk, and tablets to enable them access music, emails, and education material and learn more about Rick Smith.

The combination of the Securus and Jpay teams, services and products enable you to access quality products that offer an array of excellent security and correctional solutions at competitive prices. The overall goal of the acquisition was to assure every inmate, family and friends and the prison staff value for services and products. The two companies endeavor to provide efficient, secure, and beneficial solutions. Rick Smith would also oversee the operations at JPay and Rick Smith’s lacrosse camp.

Securus Technologies has made great strides under the leadership of Rick Smith. The company has generated increased optimism on the steps done to make incarceration secure and better. Securus has received emails that express gratitude and hope towards their services that offer the needed alternatives to fighting crime. Richard Smith believes that Securus is a secure investment because of the excellent product and service development processes that enable them to release proposals regularly to assist the relevant authorities to prevent increased social problems and solve crimes. Safety is Securus’s number one priority and resume him.

Rick Smith holds a master in mathematics and bachelor’s degree in engineering from the State University of New York, Brockport and Buffalo campuses. Richard Smith also has an M.B.A from the University of Rochester. Before Securus, Rick worked with other leading organizations in the fields of finance and technology. Rick has served as a senior executive at Eschelon Telecom, Frontier Information Technologies, and Global Crossing, formerly Frontier Corp. Currently, Rick is also the Chairman, President and Director of Securus Technology and Director of Integra Telecom. He is also a former Director at Eschelon Telecom and movie produced by Rick Smith.

May 9 2017

Jim Tananbaum, CEO of Foresite Announces a New Partner; Dr. Molly He

Foresite Capital Management is a fast-growing American company specializing in genomics and drug development investments. Foresite’s mandate is not only restricted to financing experimental treatments. No, their focus extends to encapsulate making investments in emerging diagnostics, medical devices and, on promising healthcare services. Under the able-stewardship of CEO Jim Tananbaum, the sky is no longer the limit for this organization based in San Francisco, CA, anymore. Foresite Capital has now turned its gaze on taking over the entire pharmaceutical industry.

Dr. Molly He Joins Foresite

The ambitious expansion strategy of the company recently saw them hire another highly-experienced top-level administrator. In April this year, Foresite made the announcement that they’d secured the services of Dr. Molly He to the partnership. The new signing is expected to come with a ton of positive developments, especially in the research and development department. Dr. Molly is a Ph.D. holder whose worked in the genome and pharmaceutical arena for the past 15 years. Previous to joining Foresight Capital, the revered research scientist served as one of the lead directors over at Illumina Inc.

Next-Gen Sequencing Expert

Speaking to the press shortly after the announcement, the CEO of Foresite, Jim Tananbaum couldn’t hide his joy and excitement about having Dr. Molly come work with them. After all, Molly has risen to become one of the leading authority voices in the field of next generation DNA and genome sequencing techniques. Jim referred to Dr. Molly as being an invaluable asset to Foresite and its growth prospects, moving forward.

Targeted Cancer Attacks

At her previous gig, Dr. Molly He was mostly in charge of overseeing experiments involving improving our understanding of protein reagents. The new partner has a wealth of experience working with synthetically engineered antibodies and other drugs which target cancerous cells and other autoimmune disorders prevalent in the world today. According to, Dr. Molly is the proud holder of well over 20 patents on the realm of next-generation sequencing. You can visit Peloton Therapeutics for more info.

About Jim Tananbaum

Jim is a highly respected medical researcher who attended the Harvard Medical School in the mid-to-late 80’s. Mr. Tananbaum pursued two different degrees at the same time. He balanced his medical studies with Informational Theory courses from MIT. Upon graduating, Jim didn’t start his medical career right away. Instead, he opted to increase his knowledge and that’s when he enrolled at the Harvard Business School. Jim completed his MBA studies at Harvard in 1991. The CEO has remained at Foresite Capital, based in San Francisco, for the last 7 years.

See more: